Management of Insomnia in Hospitalized Elderly Patients
DOI:
https://doi.org/10.24950/rspmi.458Keywords:
Aged, Hospitalization, Sleep Initiation and Maintenance Disorders.Abstract
There are several factors that can contribute to poor sleep quality in hospitalized elderly patients. Clinicians have a variety of non-pharmacological and pharmacological interventions available. This article aims to review the different therapeutic options. In the treatment of insomnia in hospitalized elderly patients, priority should be given to non-pharmacological measures that will improve sleep quality and improve well-being and health recovery. Some measures can be applied duringthe day, such as minimizing daytime naps, preventing and treating delirium as well as looking for and treat undiagnosed sleeping disorders.
Regarding the pharmacological measures, more than emphasize the less harmful medicines, we intend to reinforce medicines to be avoided due to side effects and impact on patients’ comorbidities, like benzodiazepines with a long half-life and antihistamines. Other drugs to consider in clinical practice are non-benzodiazepine drugs such as zolpidem and antidepressants with sedative effects such as mirtazapine and trazodone
Downloads
References
Berlin RM. Management of insomnia in hospitalized patients. Ann Intern Med. 1984;100:398-404. doi:10.7326/0003-4819-100-3-398
Meissner HH, Riemer A, Santiago SM, Stein M, Goldman MD, Williams AJ. Failure of physician documentation of sleep complaints in hospitalized patients. West J Med. 1998;169:146-9.
Isaia G, Corsinovi L, Bo M, et al. Insomnia among hospitalized elderly patients: Prevalence, clinical characteristics and risk factors. Arch Gerontol Geriatr. 2011;52:133-7. doi:10.1016/j.archger.2010.03.001
Reis C, Dias S, Rodrigues AM, Santos-Pereira P, Michelis G, Aimonino N, et al. Sleep duration, lifestyles and chronic diseases: A cross-sectional population-based study. Sleep Sci. 2018;11:217-30. doi:10.5935/1984- 0063.20180036
Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675-700. doi:10.1111/jsr.12594
Flaherty JH. Insomnia Among Hospitalized Older Persons. Clin Geriatr Med. 2008;24:51-67. doi:10.1016/j.cger.2007.08.012
Hshieh TT, Yang T, Gartaganis SL, Yue J, Inouye SK. Hospital Elder Life Program: Systematic Review and Meta-analysis of Effectiveness. Am J Geriatr Psychiatry. 2018;26:1015-33. doi:10.1016/j.jagp.2018.06.007
Lenhart SE, Buysse DJ. Treatment of insomnia in hospitalized patients. Ann Pharmacother. 2001;35:1449-57. doi:10.1345/aph.1A040
Koski RR. Treatment of Insomnia in Hospitalized Patients. US Pharm. 2011;36.
Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675-700. doi: 10.1111/jsr.12594.
Woodward M. Hypnosedatives in the Elderly. CNS Drugs. 1999;11:263-79.
Grunstein R. Insomnia. Diagnosis and management. Aust Fam Physician. 2002;31:995-1000.
Kamel NS, Gammack JK. Insomnia in the Elderly: Cause, Approach, and Treatment. Am J Med. 2006;119:463-9. doi:10.1016/j.amjmed.2005.10.051
Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: A population study. Eur Heart J. 2014;35:1382- 93. doi:10.1093/eurheartj/eht019
Direção Geral da Saúde. Norma – tratamento sintomático da ansiedade e insónia com benzodiazepinas e fármacos análogos. Número 055/2011. Lisboa: DGS; 2015.
Chiaro G, Castelnovo A, Bianco G, Maffei P, Manconi M. Severe Chronic Abuse of Zolpidem in Refractory Insomnia. J Clin Sleep Med. 2018;14:1257-9. doi:10.5664/jcsm.7240
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307-49. doi: 10.5664/jcsm.6470.
Patel D, Steinberg J, Patel P. Insomnia in the Elderly: A Review. J Clin Sleep Med. 2018;14:1017-24. doi: 10.5664/jcsm.7172.
Infarmed. Circular Informativa N.o 111/CD/8.1.7. Zolpidem – Conclusão Da Revisão de Segurança.; 2014. [accessed April 2021] Disponível em: http://www.infarmed.pt.
Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours : incidence, mechanisms and management. CNS Drugs. 2008;22:1021-36. doi: 10.2165/0023210-200822120-00005.
Stranks EK, Crowe SF. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol. 2014;36:691-700. doi: 10.1080/13803395.2014.928268.
Tom SE, Wickwire EM, Park Y, Albrecht JS. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep. 2016;39:1009-14. doi:10.5665/sleep.5742
Sun Y, Lin C, Lu C, Hsu C, Kao C. Association Between Zolpidem and Suicide: A Nationwide Population-Based Case-Control Study. Mayo Clin Proc. 2015:1-8. doi:10.1016/j.mayocp.2015.10.022
Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: A matched cohort study. BMJ Open. 2012;2. doi:10.1136/bmjopen-2012-000850
Young JS, Bourgeois JA, Hilty DM, Hardin KA. Sleep in hospitalized medical patients, Part 2: Behavioral and pharmacological management of sleep disturbances. J Hosp Med. 2009;4:50-9. doi:10.1002/jhm.397
Jaffer KY, Chang T, Vanle B, Dang J, Steiner AJ, Loera N, et al. Trazodone for Insomnia: A Systematic Review. Innov Clin Neurosci. 2017;14:24-34.
Leonard SD, Karlamangla A. Dose-Dependent Sedating and Stimulating Effects of Mirtazapine. Proc UCLA Heal. 2015;19. doi:10.1016/j. smrv.2010.11.003
Altınyazar V, Kiylioglu N. Insomnia and dementia: is agomelatine treatment helpful? Case report and review of the literature. Ther Adv Psychopharmacol. 2016;6:263-8. doi:10.1177/2045125316646064
Infarmed. Circular Informativa N.o 211/CD/8.1.7. Agomelatina – Recomendações de Segurança.; 2014. [accessed April 2021] Disponível em: http:// www.infarmed.pt
Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10-22. doi:10.1016/j.smrv.2016.06.005
European Medicines Agency. Anexo I - Resumo das Características do Medicamento - Circardin. 2012:1-29. [accessed April 2021] Disponível em: http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_Product_Information/human/000829/WC500041059.pdf.
White B, Snyder HS, Patel MV. Evaluation of Medications Used for Hospitalized Patients With Sleep Disturbances: A Frequency Analysis and Literature Review. J Pharm Pract. 2021:089719002110178. doi:10.1177/08971900211017857
Olde Rikkert MGM, Rigaud ASP. Melatonin in elderly patients with insomnia: A systematic review. Z Gerontol Geriatr. 2001;34:491-7. doi:10.1007/s003910170025
Schroeck JL, Ford J, Conway EL, et al. Review of Safety and Efficacy of Sleep Medicines in Older Adults. Clin Ther. 2016;38:2340-72. doi:10.1016/j.clinthera.2016.09.010
Alves M, Macedo IM, Távora C, Silva JF, Fonseca T. Sleep Disturbances Management in Elderly Hospitalized Patients. J Pharm Pract. 2021;8971900211053287. doi:10.1177/08971900211053287
Bromley SM. Chronic Insomnia : A Practical Review. Am Fam Physician. 1999;60:1431-8.
Staevska M, Gugutkova M, Lazarova C, Kralimarkova T, Dimitrov V, Zuberbier T, et al. Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol. 2014;171:148-54. doi: 10.1111/bjd.12846.
Hayley AC, Williams LJ, Kennedy GA, Holloway KL, Berk M, Brennan-Olsen SL, etal. Excessive daytime sleepiness and falls among older men and women: cross-sectional examination of a population-based sample. BMC Geriatr. 2015 ;15:74. doi: 10.1186/s12877-015-0068-2.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616-31. doi: 10.1111/j.1532-5415.2012.03923.x.
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469-74. doi: 10.1016/s0896-6273(00)00058-1.
Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14:1399-408. doi:10.5664/jcsm.7282
Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265-74. doi: 10.1212/ WNL.0b013e31827688ee.
Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CL, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21:125-39. doi: 10.1016/S1474- 4422(21)00436-1. Erratum in: Lancet Neurol. 2022 Jan 20: Erratum in: Lancet Neurol. 2022;21:e6.
Mieda M, Tsujino N, Sakurai T. Differential roles of orexin receptors in the regulation of sleep/ wakefulness. Front Endocrinol. 2013;4:57. doi: 10.3389/fendo.2013.00057.
Campos L. Protocolos em Medicina interna. Lisboa: Lidel ; 2013.
Downloads
Published
How to Cite
License
Copyright (c) 2022 Medicina Interna
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
